IL126152A0 - Recombinant adenoviral vectors for human tumor gene therapy - Google Patents

Recombinant adenoviral vectors for human tumor gene therapy

Info

Publication number
IL126152A0
IL126152A0 IL12615297A IL12615297A IL126152A0 IL 126152 A0 IL126152 A0 IL 126152A0 IL 12615297 A IL12615297 A IL 12615297A IL 12615297 A IL12615297 A IL 12615297A IL 126152 A0 IL126152 A0 IL 126152A0
Authority
IL
Israel
Prior art keywords
gene therapy
human tumor
adenoviral vectors
recombinant adenoviral
tumor gene
Prior art date
Application number
IL12615297A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL126152A0 publication Critical patent/IL126152A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12615297A 1996-03-14 1997-03-12 Recombinant adenoviral vectors for human tumor gene therapy IL126152A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (1)

Publication Number Publication Date
IL126152A0 true IL126152A0 (en) 1999-05-09

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12615297A IL126152A0 (en) 1996-03-14 1997-03-12 Recombinant adenoviral vectors for human tumor gene therapy

Country Status (19)

Country Link
US (1) US20030082150A1 (ja)
EP (1) EP0889969B1 (ja)
JP (1) JP2000507229A (ja)
KR (1) KR19990087718A (ja)
CN (1) CN1218512A (ja)
AT (1) ATE309382T1 (ja)
AU (1) AU732288B2 (ja)
BR (1) BR9707994A (ja)
CA (1) CA2248612A1 (ja)
CZ (1) CZ295967B6 (ja)
DE (1) DE69734574T2 (ja)
DK (1) DK0889969T3 (ja)
ES (1) ES2252779T3 (ja)
FR (1) FR2746110B1 (ja)
HU (1) HUP9902150A3 (ja)
IL (1) IL126152A0 (ja)
NO (1) NO984052L (ja)
SK (1) SK124698A3 (ja)
WO (1) WO1997034009A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
DE60238044D1 (de) * 2001-03-27 2010-12-02 Univ New York Tumortherapie mit vektoren auf sindbis virus-basis
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
ES2310924T3 (es) * 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.

Also Published As

Publication number Publication date
NO984052D0 (no) 1998-09-03
ATE309382T1 (de) 2005-11-15
DE69734574D1 (de) 2005-12-15
NO984052L (no) 1998-09-03
EP0889969B1 (fr) 2005-11-09
US20030082150A1 (en) 2003-05-01
CN1218512A (zh) 1999-06-02
WO1997034009A1 (fr) 1997-09-18
AU2164197A (en) 1997-10-01
ES2252779T3 (es) 2006-05-16
FR2746110A1 (fr) 1997-09-19
DK0889969T3 (da) 2006-03-27
KR19990087718A (ko) 1999-12-27
HUP9902150A3 (en) 2000-12-28
CZ295967B6 (cs) 2005-12-14
JP2000507229A (ja) 2000-06-13
FR2746110B1 (fr) 1998-04-17
CA2248612A1 (fr) 1997-09-18
AU732288B2 (en) 2001-04-12
CZ291598A3 (cs) 1998-12-16
EP0889969A1 (fr) 1999-01-13
SK124698A3 (en) 1999-05-07
BR9707994A (pt) 1999-07-27
DE69734574T2 (de) 2006-07-13
HUP9902150A2 (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
HU9500732D0 (en) Defective adenovirus vectors and use thereof in gene therapy
HK1067645A1 (en) Tumor antigen peptides originating in cyclophilin b
PL354348A1 (en) Compounds and methods for therapy and diagnosis of lung cancer
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
PL314239A1 (en) Recombinated adenovirus vector and method of using it
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
NO953684L (no) Fremgangsmåte for fremstilling av kreftvaksiner
WO1999032516A3 (en) Pharmaceutical compositions containing the long pentraxin ptx3
EP1455840A4 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR TNF-ALPHA
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales